checkAd
    Startseite > Aktien > Revance Therapeutics > Nachrichten
    Revance Therapeutics Aktie
    3,3200
     
    USD
    -22,61 %
    -0,9700 USD
    Letzter Kurs 11.05.24 Nasdaq
    3,3100
     
    USD
    48.200 STK
    Geldkurs 10.05.24
    3,3200
     
    USD
    17.000 STK
    Briefkurs 10.05.24
    ISIN: US7613301099 · WKN: A1XD3D · SYM: RVNC · USA

    Neueste Nachrichten

    Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update
    09.05.24 · Business Wire (engl.) · Revance Therapeutics
    Revance to Release First Quarter 2024 Financial Results on Thursday, May 9, 2024
    02.05.24 · Business Wire (engl.) · Revance Therapeutics
    Revance to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting
    12.04.24 · Business Wire (engl.) · Revance Therapeutics
    Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    27.03.24 · Business Wire (engl.) · Revance Therapeutics
    Revance Announces Pricing of $100.0 Million Public Offering of Common Stock
    04.03.24 · Business Wire (engl.) · Revance Therapeutics
    Revance Announces Proposed Public Offering of Common Stock
    04.03.24 · Business Wire (engl.) · Revance Therapeutics
    Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update
    28.02.24 · Business Wire (engl.) · Revance Therapeutics
    Revance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024
    21.02.24 · Business Wire (engl.) · Revance Therapeutics
    Revance to Participate in Upcoming Investor Conferences
    21.02.24 · Business Wire (engl.) · Revance Therapeutics
    Revance Receives Permanent J-Code for DAXXIFY and Announces Publication of DAXXIFY Pivotal Study (ASPEN-1) Results in Neurology
    02.02.24 · Business Wire (engl.) · Revance Therapeutics
    Revance to Participate in the Guggenheim 6th Annual Biotechnology Conference
    01.02.24 · Business Wire (engl.) · Revance Therapeutics
    Revance Provides Corporate Update, Preliminary Fourth Quarter and Full Year 2023 Financial Results, and Financial Outlook
    08.01.24 · Business Wire (engl.) · Revance Therapeutics